Wenbo Cheng MD, Xue Chen MD, Shiyi Wang MM, Mu Qin MD, Zonghan Zhao MD
{"title":"Pulsed Field Ablation with the Pentaspline Catheter vs Radiofrequency Ablation for Recurrent Atrial Fibrillation","authors":"Wenbo Cheng MD, Xue Chen MD, Shiyi Wang MM, Mu Qin MD, Zonghan Zhao MD","doi":"10.1016/j.cjco.2026.05.009","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Pulsed field ablation (PFA) is a non-thermal energy modality for catheter ablation. Although recent studies have demonstrated that PFA is noninferior to radiofrequency ablation (RFA) for the initial treatment of atrial fibrillation (AF), its comparative efficacy and safety in patients who had AF recurrence following the initial ablation procedure remain unknown.</div></div><div><h3>Methods</h3><div>From July 1, 2024 to September 30, 2024, 223 consecutive patients who had AF recurrence following the initial ablation procedure were prospectively enrolled from 2 participating centres and underwent either PFA using the pentaspline catheter (PFA group, n = 77) or RFA (RFA group, n = 146), based on clinical judgment. The effectiveness endpoint was freedom from AF/atrial tachycardia (AT) recurrence at 12 months.</div></div><div><h3>Results</h3><div>At 12 months, no significant difference was present in the rate of freedom from AF/AT recurrence between the PFA and RFA groups (71.4% vs 67.8%; log-rank <em>P</em> = 0.514; hazard ratio 0.85, 95% confidence interval 0.52-1.38). Similarly, the incidence of safety endpoints did not differ significantly between the 2 groups (2.6% vs 3.4%; <em>P</em> = 0.947).</div></div><div><h3>Conclusions</h3><div>In patients who had AF recurrence following the initial ablation procedure, PFA using a pentaspline catheter demonstrated comparable effectiveness and safety to RFA, with similar rates of freedom from AF/AT recurrence and adverse events at 12 months.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"8 9","pages":"Pages 1158-1165"},"PeriodicalIF":2.1000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CJC Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589790X26002143","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Pulsed field ablation (PFA) is a non-thermal energy modality for catheter ablation. Although recent studies have demonstrated that PFA is noninferior to radiofrequency ablation (RFA) for the initial treatment of atrial fibrillation (AF), its comparative efficacy and safety in patients who had AF recurrence following the initial ablation procedure remain unknown.
Methods
From July 1, 2024 to September 30, 2024, 223 consecutive patients who had AF recurrence following the initial ablation procedure were prospectively enrolled from 2 participating centres and underwent either PFA using the pentaspline catheter (PFA group, n = 77) or RFA (RFA group, n = 146), based on clinical judgment. The effectiveness endpoint was freedom from AF/atrial tachycardia (AT) recurrence at 12 months.
Results
At 12 months, no significant difference was present in the rate of freedom from AF/AT recurrence between the PFA and RFA groups (71.4% vs 67.8%; log-rank P = 0.514; hazard ratio 0.85, 95% confidence interval 0.52-1.38). Similarly, the incidence of safety endpoints did not differ significantly between the 2 groups (2.6% vs 3.4%; P = 0.947).
Conclusions
In patients who had AF recurrence following the initial ablation procedure, PFA using a pentaspline catheter demonstrated comparable effectiveness and safety to RFA, with similar rates of freedom from AF/AT recurrence and adverse events at 12 months.
脉冲场消融(PFA)是一种用于导管消融的非热能方式。尽管最近的研究表明,PFA在房颤(AF)的初始治疗中并不亚于射频消融(RFA),但其在初始消融后房颤复发患者中的相对疗效和安全性仍不清楚。方法从2024年7月1日至2024年9月30日,前瞻性纳入来自2个参与中心的223例首次消融后房颤复发患者,根据临床判断分别采用pentaspline导管PFA (PFA组,n = 77)或RFA (RFA组,n = 146)。有效性终点为12个月无房颤/房性心动过速(AT)复发。结果12个月后,PFA组和RFA组AF/AT复发率无显著差异(71.4% vs 67.8%; log-rank P = 0.514;风险比0.85,95%可信区间0.52-1.38)。同样,两组间安全终点的发生率无显著差异(2.6% vs 3.4%; P = 0.947)。结论:对于在初始消融手术后发生房颤复发的患者,使用pentaspline导管进行PFA的有效性和安全性与RFA相当,在12个月时房颤/房颤复发和不良事件的发生率相似。